Adverse effects of heparin.
暂无分享,去创建一个
[1] E. Bröcker,et al. Tolerance to intravenous heparin in patients with delayed‐type hypersensitivity to heparins: a prospective study , 2005, British journal of haematology.
[2] W. Fraser,et al. Prospective observational study of bone mineral density during pregnancy: low molecular weight heparin versus control. , 2004, Human reproduction.
[3] R. Beyth,et al. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.
[4] J. Herbert,et al. Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia. , 1997, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[5] M. J. Hursting,et al. Reducing Harm Associated with Anticoagulation , 2009, Drug safety.
[6] A. Greinacher,et al. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation , 2005, Thrombosis and Haemostasis.
[7] M. Monreal,et al. Adverse effects of three different forms of heparin therapy: thrombocytopenia, increased transaminases, and hyperkalaemia , 2004, European Journal of Clinical Pharmacology.
[8] L. Alberio. Heparin-induced thrombocytopenia: some working hypotheses on pathogenesis, diagnostic strategies and treatment , 2008, Current opinion in hematology.
[9] O. Reikerås,et al. Preoperative versus Postoperative Initiation of Dalteparin Thromboprophylaxis in THA , 2010 .
[10] E. Ohman,et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. , 1998, Chest.
[11] M. Poncz,et al. Immune Vascular Injury in Heparin- Induced Thrombocytopenia , 2003 .
[12] I. Greer,et al. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. , 2005, Blood.
[13] J. Hirsh,et al. Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a nested cohort study. , 2005, Chest.
[15] O. Hélénon,et al. Randomized Trial of Subcutaneous Low‐Molecular‐Weight Heparin CY 216 (Fraxiparine) Compared With Intravenous Unfractionated Heparin in the Curative Treatment of Submassive Pulmonary Embolism: A Dose‐Ranging Study , 1992, Circulation.
[16] P. Wells,et al. Efficacy of low- molecular- weight- heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials. , 2009, Thrombosis research.
[17] M. Alhenc-Gelas,et al. Adjusted Versus Fixed Doses of the Low-Molecular-Weight Heparin Fragmin in the Treatment of Deep Vein Thrombosis , 1994, Thrombosis and Haemostasis.
[18] R. Aster,et al. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis recognize different epitopes on heparin: platelet factor 4. , 1998, Blood.
[19] M. Schindewolf,et al. Molecular weight determines the frequency of delayed type hypersensitivity reactions to heparin and synthetic oligosaccharides , 2005, Thrombosis and Haemostasis.
[20] T. Kohlmann,et al. The temporal profile of the anti-PF4/heparin immune response. , 2009, Blood.
[21] T. Warkentin,et al. Generation of platelet-derived microparticles and procoagulant activity by heparin-induced thrombocytopenia IgG/serum and other IgG platelet agonists: a comparison with standard platelet agonists. , 1999, Platelets.
[22] S. Alban. [Natural and synthetic glycosaminoglycans. Molecular characteristics as the basis of distinct drug profiles]. , 2008, Hamostaseologie.
[23] B. Eriksson,et al. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. , 2005, Blood.
[24] W. Weitschies,et al. Close Approximation of Two Platelet Factor 4 Tetramers by Charge Neutralization Forms the Antigens Recognized by HIT Antibodies , 2006, Arteriosclerosis, thrombosis, and vascular biology.
[25] A. Greinacher,et al. Role of Sulfated Polysaccharides in the Pathogenesis of Heparin- Induced Thrombocytopenia , 2003 .
[26] A. Chernoff. Anaphylactic reaction following injection of heparin. , 1950, The New England journal of medicine.
[27] J H Lewis,et al. Drug-induced liver disease. , 2000, Clinics in liver disease.
[28] I. Greer,et al. Low molecular weight heparin in pregnancy: current issues , 2005, British journal of haematology.
[29] P. Wells,et al. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. , 2005, Blood.
[30] R. Apsner,et al. Dalteparin-induced alopecia in hemodialysis patients: reversal by regional citrate anticoagulation. , 2001, Blood.
[31] C. Schizas,et al. The effect of anticoagulant pharmacotherapy on fracture healing , 2008, Expert opinion on pharmacotherapy.
[32] P. Itin,et al. Delayed hypersensitivity to one low‐molecular‐weight heparin with tolerance of other low‐molecular‐weight heparins , 1995, The British journal of dermatology.
[33] B. Chong,et al. Heparin-induced Thrombocytopenia: Towards Consensus , 1998, Thrombosis and Haemostasis.
[34] W. Aberer,et al. Delayed-type hypersensitivity to low molecular weight heparins and heparinoids: cross-reactivity does not depend on molecular weight. Commentary. , 2007 .
[35] S. Sakamoto,et al. Early onset of immunological heparin‐induced thrombocytopenia in acute myocardial infarction , 1997, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[36] W. Aberer,et al. Acute generalized exanthematous pustulosis from dalteparin. , 2007, Journal of the American Academy of Dermatology.
[37] M. Butcher,et al. The effects of heparin and low molecular weight heparins on bone. , 2008, Thrombosis research.
[38] S Alban,et al. Pharmacological strategies for inhibition of thrombin activity. , 2008, Current pharmaceutical design.
[39] L. Kaklamanis,et al. Diffuse alopecia in a hemodialysis patient caused by a low-molecular-weight heparin, tinzaparin. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[40] S. Frostick,et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE‐MODEL randomized trial , 2007, Journal of thrombosis and haemostasis : JTH.
[41] A. Bircher,et al. Immediate type hypersensitivity to low molecular weight heparins and tolerance of unfractioned heparin and fondaparinux , 2006, Allergy.
[42] W. Fry,et al. HEPARIN REACTIONS IN PATIENTS WITH VASCULAR DISEASE. , 1965, Archives of surgery.
[43] W. Aberer,et al. Delayed-type skin reaction to the heparin-alternative danaparoid. , 2000, Journal of the American Academy of Dermatology.
[44] Lijuan Zhang,et al. Molecular mechanism underlines heparin-induced thrombocytopenia and thrombosis. , 2010, Progress in molecular biology and translational science.
[45] K. Alexander,et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. , 2005, JAMA.
[46] R. W. Meikle,et al. Alopecia following Treatment with Dextran Sulphate and Other Anticoagulant Drugs , 1958, British medical journal.
[47] Michael Weis,et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. , 2008, European heart journal.
[48] B. Dahlbäck,et al. The multiple faces of the partial thromboplastin time APTT , 2004, Journal of thrombosis and haemostasis : JTH.
[49] R. Hull,et al. Antithrombotic therapy for venous thromboembolic disease. , 1986, Chest.
[50] Y. Gruel,et al. Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia. , 2001 .
[51] A. Disch,et al. Effects of Fondaparinux Compared with Dalteparin, Enoxaparin and Unfractionated Heparin on Human Osteoblasts , 2003, Calcified Tissue International.
[52] A. Bircher,et al. Delayed‐type hypersensitivity to the ultra‐low‐molecular‐weight heparin fondaparinux , 2004, Contact dermatitis.
[53] R. Paus. Hair growth inhibition by heparin in mice: a model system for studying the modulation of epithelial cell growth by glycosaminoglycans? , 1991, The British journal of dermatology.
[54] P. Prandoni,et al. Predicting recurrences or major bleeding in cancer patients with venous thromboembolism , 2008, Thrombosis and Haemostasis.
[55] M. Takami,et al. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity. , 2007, Bone.
[56] E. Lindhoff‐Last,et al. Hirudin determination in plasma can be strongly influenced by the prothrombin level. , 2000, Thrombosis research.
[57] M. Monreal,et al. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry , 2008, Thrombosis and Haemostasis.
[58] A. Pisciotta,et al. ALOPECIA AND OTHER TOXIC EFFECTS OF HEPARIN AND SYNTHETIC HEPARINOIDS , 1954, The American journal of the medical sciences.
[59] G. Sacchi,et al. Protective effects of heparin on hepatic ischemia and reperfusion lesions in rabbits. , 2009, Transplantation proceedings.
[60] P. Miller. Guidelines for the diagnosis of osteoporosis: T-scores vs fractures , 2007, Reviews in Endocrine and Metabolic Disorders.
[61] G. Raskob,et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.
[62] A. Cohen,et al. Heparin for the prevention of venous thromboembolism in acutely ill medical patients (excluding stroke and myocardial infarction). , 2014, The Cochrane database of systematic reviews.
[63] J. Hirsh,et al. A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats. , 1997, Blood.
[64] S. Kahn,et al. Long‐term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial , 2007, Journal of thrombosis and haemostasis : JTH.
[65] J. Kelton,et al. A spontaneous prothrombotic disorder resembling heparin-induced thrombocytopenia. , 2008, The American journal of medicine.
[66] B. Lobo,et al. Fondaparinux for the treatment of patients with acute heparininduced thrombocytopenia , 2007, Thrombosis and Haemostasis.
[67] G. Wanner,et al. Cbfa-1 (Runx-2) and Osteocalcin Expression by Human Osteoblasts in Heparin Osteoporosis in Vitro , 2006, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.
[68] S. MacIsaac,et al. Low-molecular-weight heparin prophylaxis: preoperative versus postoperative initiation in patients undergoing elective hip surgery. , 2001, Thrombosis research.
[69] Salim Yusuf,et al. Relationship of Activated Partial Thromboplastin Time to Coronary Events and Bleeding in Patients With Acute Coronary Syndromes Who Receive Heparin , 2003, Circulation.
[70] V. Hiilesmaa,et al. Postpartum Bone Mineral Density in Women Treated for Thromboprophylaxis with Unfractionated Heparin or LMW Heparin , 2002, Thrombosis and Haemostasis.
[71] U. Jappe. Allergy to heparins and anticoagulants with a similar pharmacological profile: an update , 2006, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[72] A. Trautmann,et al. The complex clinical picture of side effects to anticoagulation. , 2010, The Medical clinics of North America.
[73] N. Heddle,et al. Laboratory diagnosis of immune heparin-induced thrombocytopenia. , 2003, Current hematology reports.
[74] M. Bhandari,et al. A histomorphometric evaluation of heparin-induced bone loss after discontinuation of heparin treatment in rats. , 1999, Blood.
[75] L. Rauova,et al. Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. , 2005, Blood.
[76] T. Ortel,et al. Heparin-induced thrombocytopenia. , 2006, Seminars in hematology.
[77] C. Christiansen. Osteoporosis: diagnosis and management today and tomorrow. , 1995, Bone.
[78] M. Rodger,et al. Heparin-induced osteoporosis and pregnancy , 2008, Current opinion in pulmonary medicine.
[79] B. Eriksson,et al. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. , 2002, Archives of internal medicine.
[80] M. Monreal,et al. Comparison of Subcutaneous Unfractionated Heparin with a Low Molecular Weight Heparin (Fragmin®) in Patients with Venous Thromboembolism and Contraindications to Coumarin , 1994, Thrombosis and Haemostasis.
[81] T. Warkentin. Agents for the treatment of heparin-induced thrombocytopenia. , 2010, Hematology/oncology clinics of North America.
[82] J. Philippé,et al. A clinical-laboratory approach contributing to a rapid and reliable diagnosis of heparin-induced thrombocytopenia. , 2008, Thrombosis research.
[83] G. Arepally,et al. Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8. , 2001, Blood.
[84] V. Marder,et al. Anti‐PF4/heparin antibody formation postorthopedic surgery thromboprophylaxis: the role of non‐drug risk factors and evidence for a stoichiometry‐based model of immunization , 2010, Journal of thrombosis and haemostasis : JTH.
[85] R. Bergemann,et al. Efficacy and safety of low molecular weight heparin, unfractionated heparin and warfarin for thrombo-embolism prophylaxis in orthopaedic surgery: a meta-analysis of randomised clinical trials. , 1997, Haemostasis.
[86] M. Schindewolf,et al. Need for an increasing awareness for heparin-induced skin lesions , 2010 .
[87] J. Utikal,et al. Management of cutaneous type IV hypersensitivity reactions induced by heparin , 2006, Thrombosis and Haemostasis.
[88] J. Corson,et al. Efficacy and Safety of Low Molecular Weight Heparin (Ardeparin Sodium) Compared to Warfarin for the Prevention of Venous Thromboembolism after Total Knee Replacement Surgery: A Double-blind, Dose-ranging Study , 1997, Thrombosis and Haemostasis.
[89] C. Sigouin,et al. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin‐induced thrombocytopenia in two clinical settings , 2006, Journal of thrombosis and haemostasis : JTH.
[90] Clifford W Colwell,et al. Prevention of Venous Thromboembolism* American College of Chest Physicians Evidence- Based Clinical Practice Guidelines (8th Edition) , 2008 .
[91] H. Riess,et al. Blood Coagulation , Fibrinolysis and Cellular Haemostasis 252 Fixed-dose , body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis , 2003 .
[92] B. Eriksson,et al. Oral, direct Factor Xa inhibition with BAY 59‐7939 for the prevention of venous thromboembolism after total hip replacement , 2006, Journal of thrombosis and haemostasis : JTH.
[93] A. Bircher,et al. Hypersensitivity reactions to anticoagulant drugs. , 2008, Current pharmaceutical design.
[94] I. Marzi,et al. Low allergenic potential with fondaparinux: results of a prospective investigation. , 2010, Mayo Clinic proceedings.
[95] J. Douketis,et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.
[96] K. Alexander,et al. Unfractionated heparin dosing and risk of major bleeding in non-ST-segment elevation acute coronary syndromes. , 2008, American heart journal.
[97] D. Bergqvist. Low molecular weight heparin for the prevention of venous thromboembolism after abdominal surgery , 2004, The British journal of surgery.
[98] P. Koch,et al. Delayed-type hypersensitivity skin reactions caused by subcutaneous unfractionated and low-molecular-weight heparins: tolerance of a new recombinant hirudin. , 2000, Journal of the American Academy of Dermatology.
[99] A. Greinacher,et al. The direct thrombin inhibitor hirudin , 2008, Thrombosis and Haemostasis.
[100] T. Dahlman,et al. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. , 1993, American journal of obstetrics and gynecology.
[101] J. Hirsh,et al. Histomorphometric analysis of the effects of standard heparin on trabecular bone in vivo. , 1996, Blood.
[102] M. Prins,et al. Once versus twice daily LMWH for the initial treatment of venous thromboembolism. , 2002, The Cochrane database of systematic reviews.
[103] M. Haugh,et al. Factor Xa inhibition: correlation between the plasma levels of anti-Xa activity and occurrence of thrombosis and haemorrhage. , 1993, Haemostasis.
[104] T. Warkentin,et al. Heparin‐induced thrombocytopenia: pathogenesis and management , 2003, British journal of haematology.
[105] T. Kohlmann,et al. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis , 2005, Thrombosis and Haemostasis.
[106] S. Goldhaber,et al. Anticoagulants and Transaminase Elevation , 2006, Circulation.
[107] A. Greinacher,et al. Heparin-induced anaphylactic and anaphylactoid reactions: two distinct but overlapping syndromes , 2009, Expert opinion on drug safety.
[108] J. Kelton,et al. Temporal aspects of heparin-induced thrombocytopenia. , 2001, The New England journal of medicine.
[109] P. Stein,et al. Incidence of thrombocytopenia in hospitalized patients with venous thromboembolism. , 2009, The American journal of medicine.
[110] T. Burnakis,et al. Transaminase elevations in patients receiving bovine or porcine heparin. , 1984, Annals of internal medicine.
[111] F. Dentali,et al. Meta-Analysis: Low-Molecular-Weight Heparin and Bleeding in Patients with Severe Renal Insufficiency , 2006, Annals of Internal Medicine.
[112] A. Bircher,et al. Hypersensitivity reactions to anticoagulant drugs: diagnosis and management options , 2006, Allergy.
[113] J. Ansell,et al. Oral anticoagulation with factor Xa and thrombin inhibitors: on the threshold of change , 2009, Current opinion in hematology.
[114] B. Chong,et al. Plasma P-selectin is increased in thrombotic consumptive platelet disorders , 1994 .
[115] T. Warkentin. Think of HIT. , 2006, Hematology. American Society of Hematology. Education Program.
[116] E. Frenkel,et al. Clinical Aspects of Heparin-Induced Thrombocytopenia and Thrombosis and other Side Effects of Heparin Therapy , 1999, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.
[117] M. Schindewolf,et al. The influence of heparin’s molecular weight and the incidence of delayed type hypersensitivity reactions revisited; in response to Grims et al., Br J Dermatol 2007; 157:514–17 , 2008, The British journal of dermatology.
[118] Barbara Mulloy,et al. Heparin - A Century of Progress , 2012, Handbook of Experimental Pharmacology.
[119] J. Labarca,et al. Heparin-induced transaminase elevations: a prospective study. , 1993, International journal of clinical pharmacology, therapy, and toxicology.
[120] J. Hirsh. Heparin and low-molecular weight heparins , 1992 .
[121] V. Kakkar,et al. Efficacy and safety of two regimens of low molecular weight heparin fragment (Fragmin) in preventing postoperative venous thrombolism. , 1986, Haemostasis.
[122] Y. Shoenfeld,et al. Anti-platelet factor 4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells. , 2002, International immunology.
[123] J. Hirsh,et al. The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria. , 1995, Blood.
[124] L. Lopez. Low‐Molecular‐Weight Heparins Are Essentially the Same for Treatment and Prevention of Venous Thromboembolism , 2001, Pharmacotherapy.
[125] T. Warkentin. Fondaparinux versus direct thrombin inhibitor therapy for the management of heparin-induced thrombocytopenia (HIT) – Bridging the River Coumarin , 2007, Thrombosis and Haemostasis.
[126] T. Kohlmann,et al. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. , 2006, Blood.
[127] I. Ng,et al. Low Molecular Weight Heparin‐Induced Liver Toxicity , 2001, Journal of clinical pharmacology.
[128] T. Warkentin,et al. Non‐necrotizing heparin‐induced skin lesions and the 4T’s score , 2010, Journal of thrombosis and haemostasis : JTH.
[129] William Wijns,et al. [Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes]. , 2007, Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology.
[130] H. Bounameaux,et al. Duration of anticoagulation therapy for venous thromboembolism. , 2008, Hematology. American Society of Hematology. Education Program.
[131] G. Wanner,et al. Low molecular weight heparin-induced skin necrosis—a systematic review , 2005, Langenbeck's Archives of Surgery.
[132] T. Warkentin. Clinical picture of heparin-induced thrombocytopenia , 2012 .
[133] D. Moher,et al. Heparin versus placebo for acute coronary syndromes. , 2008, The Cochrane database of systematic reviews.
[134] C. Nelson-Piercy. Hazards of heparin: allergy, heparin-induced thrombocytopenia and osteoporosis. , 1997, Bailliere's clinical obstetrics and gynaecology.
[135] G. Guyatt,et al. The 4Ts scoring system for heparin-induced thrombocytopenia in medical-surgical intensive care unit patients. , 2010, Journal of critical care.
[136] P. Monagle,et al. Alopecia and dalteparin: a previously unreported association. , 2000, Blood.
[137] J. Kelton,et al. Heparin-induced thrombocytopenia: a historical perspective. , 2008, Blood.
[138] E. Ohman,et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. , 2001, Chest.
[139] J. Low,et al. Timely diagnosis and management of heparin‐induced thrombocytopenia in a frequent request, low incidence single centre using clinical 4T’s score and particle gel immunoassay , 2008, British journal of haematology.
[140] M. Khamashta,et al. Review: Low-molecular-weight heparin-induced osteoporosis and osteoporotic fractures: A myth or an existing entity? , 2010, Lupus.
[141] A. Greinacher,et al. Heparin‐induced thrombocytopenia: a prospective study on the incidence, platelet‐activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes , 2007, Journal of thrombosis and haemostasis : JTH.
[142] M. Uchiba,et al. Dalteparin, a low molecular weight heparin, attenuates inflammatory responses and reduces ischemia-reperfusion–induced liver injury in rats* , 2006, Critical care medicine.
[143] P. Haentjens. Thromboembolic prophylaxis in orthopaedic trauma patients: a comparison between a fixed dose and an individually adjusted dose of a low molecular weight heparin (nadroparin calcium) , 1996, Injury.
[144] J. Kelton,et al. Studies of the immune response in heparin-induced thrombocytopenia. , 2009, Blood.
[145] E. Moore,et al. Case study: contamination of heparin with oversulfated chondroitin sulfate. , 2012, Handbook of experimental pharmacology.
[146] H. Ackermann,et al. Heparin‐induced non‐necrotizing skin lesions: rarely associated with heparin‐induced thrombocytopenia , 2010, Journal of thrombosis and haemostasis : JTH.
[147] I. Bernstein. Anaphylaxis to heparin sodium; report of a case, with immunologic studies. , 1956, Journal of the American Medical Association.
[148] M. Nauck,et al. The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia. , 2010, Blood.
[149] V. Pettilä,et al. Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. , 1999, Thrombosis research.
[150] P. Watkins,et al. Are patients with elevated liver tests at increased risk of drug-induced liver injury? , 2004, Gastroenterology.
[151] T. Kohlmann,et al. Heparin‐induced thrombocytopenia – therapeutic concentrations of danaparoid, unlike fondaparinux and direct thrombin inhibitors, inhibit formation of platelet factor 4–heparin complexes , 2008, Journal of thrombosis and haemostasis : JTH.
[152] J. Hansen,et al. Liver sinusoidal endothelial cells are the principal site for elimination of unfractionated heparin from the circulation. , 2008, American journal of physiology. Gastrointestinal and liver physiology.
[153] T. Warkentin. Heparin‐induced skin lesions , 1996, British journal of haematology.
[154] A. Greinacher,et al. Heparin‐induced thrombocytopenia , 2009, Journal of thrombosis and haemostasis : JTH.
[155] J. Hansen,et al. Heparin induces mobilization of osteoprotegerin into the circulation , 2007, Thrombosis and Haemostasis.
[156] S. Hoerstrup,et al. Effect of low molecular weight heparin (dalteparin) and fondaparinux (Arixtra®) on human osteoblasts in vitro , 2005, The British journal of surgery.
[157] P. Lips,et al. Effects of short-term low-dose heparin administration on biochemical parameters of bone turnover. , 1993, Bone and mineral.
[158] J. Hirsh,et al. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.
[159] C. Colwell,et al. Prevention of venous thromboembolism. , 1994, Chest.
[160] J. Kelton,et al. The Pathogenesis of Venous Limb Gangrene Associated with Heparin-Induced Thrombocytopenia , 1997, Annals of Internal Medicine.
[161] L. Rauova,et al. Heparin‐induced thrombocytopenia: An autoimmune disorder regulated through dynamic autoantigen assembly/disassembly , 2007, Journal of clinical apheresis.
[162] J. Eikelboom,et al. Bleeding Complications in Acute Coronary Syndromes and Percutaneous Coronary Intervention: Predictors, Prognostic Significance, and Paradigms for Reducing Risk , 2007, Clinical cardiology.
[163] P. Gleason,et al. Elevation of Hepatic Transaminases after Enoxaparin Use: Case Report and Review of Unfractionated and Low‐Molecular‐Weight Heparin‐Induced Hepatotoxicity , 2001, Pharmacotherapy.
[164] D. Hawkins,et al. Minimising the risk of heparin-induced osteoporosis during pregnancy , 2005, Expert opinion on drug safety.
[165] A. James,et al. Bone density changes in women who receive thromboprophylaxis in pregnancy. , 2005, American journal of obstetrics and gynecology.
[166] B. Mulloy. The specificity of interactions between proteins and sulfated polysaccharides. , 2005, Anais da Academia Brasileira de Ciencias.
[167] E. Gabazza,et al. Aberrations of the Tissue Factor Pathway in Patients Positive for Lupus Anticoagulant , 1999, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.
[168] L. Śliwiński,et al. Effects of standard heparin and low-molecular-weight heparins on the formation of murine osteoclasts in vitro. , 2005, Pharmacological reports : PR.
[169] P. Ejstrud,et al. Dose Relation in the Prevention of Proximal Vein Thrombosis with a Low Molecular Weight Heparin (Tinzaparin) in Elective Hip Arthroplasty , 2000, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.
[170] J. Hallett. Randomized trial of subcutaneous low-molecular weight heparin CY 216 (Fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism: Théry C, Simonneau G, Meyer G, et al. Circulation 1992; 85: 1380–1389 , 1993 .
[171] W. Weitschies,et al. Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings. , 2008, Thrombosis research.
[172] B. Chong,et al. Heparin-induced thrombocytopenia associated with fondaparinux. , 2007, The New England journal of medicine.
[173] A. Ekkernkamp,et al. Thromboseprophylaxe in unfallchirurgischen Abteilungen in Deutschland , 2009, Der Unfallchirurg.
[174] A. Turpie,et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. , 1999, The New England journal of medicine.
[175] Y.‐Y. Wang,et al. Enoxaparin‐induced alopecia in patients with cerebral venous thrombosis , 2006, Journal of clinical pharmacy and therapeutics.
[176] Sundeep Khosla,et al. The Roles of Osteoprotegerin and Osteoprotegerin Ligand in the Paracrine Regulation of Bone Resorption , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[177] M. O’Donnell,et al. Major Bleeding, Mortality, and Efficacy of Fondaparinux in Venous Thromboembolism Prevention Trials , 2009, Circulation.
[178] E. Antman,et al. Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. , 2007, European heart journal.
[179] A. Lincoff,et al. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.
[180] L. Rauova,et al. Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. , 2006, Blood.
[181] T. Ittermann,et al. Heparin‐induced thrombocytopenia: towards standardization of platelet factor 4/heparin antigen tests , 2010, Journal of thrombosis and haemostasis : JTH.
[182] I. Gouin-Thibault,et al. A need for evidence-based clinical practice guidelines for the use of heparins in the elderly , 2010, Clinical interventions in aging.
[183] M. Torres,et al. Lymphocyte proliferation response in patients with delayed hypersensitivity reactions to heparins , 2009, The British journal of dermatology.
[184] J. Bassand,et al. Impact of anaemia, bleeding, and transfusions in acute coronary syndromes: a shift in the paradigm. , 2007, European heart journal.
[185] M. Kaplan,et al. Evaluation of abnormal liver-enzyme results in asymptomatic patients. , 2000, The New England journal of medicine.
[186] A. Trouvin,et al. Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss , 2010, Clinical interventions in aging.
[187] H. Kleinman,et al. Heparanase regulates murine hair growth. , 2005, The American journal of pathology.
[188] G. Lip,et al. Heparin-induced thrombocytopenia. A contemporary clinical approach to diagnosis and management. , 2009, Chest.
[189] H. Riess,et al. A randomized, double‐blind study of certoparin vs. unfractionated heparin to prevent venous thromboembolic events in acutely ill, non‐surgical patients: CERTIFY Study , 2010, Journal of thrombosis and haemostasis : JTH.
[190] G. Raskob,et al. Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery. , 2003, Chest.
[191] S. Gates,et al. Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period. , 2014, The Cochrane database of systematic reviews.
[192] E. H. Terzi,et al. The preventive effect of low molecular weight heparin on CCL₄-induced necrosis and apoptosis in rat liver. , 2010, Annals of hepatology.
[193] S. Laporte,et al. Meta‐analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery , 2001, The British journal of surgery.
[194] A. Trautmann,et al. Management of allergy to heparins in postoperative care: subcutaneous allergy and intravenous tolerance. , 2008, Dermatology online journal.
[195] C. Chapelle,et al. Thrombin generation and heparin‐induced thrombocytopenia , 2009, Journal of thrombosis and haemostasis : JTH.
[196] Y. Gruel,et al. Prospective evaluation of the ‘4Ts’ score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin‐induced thrombocytopenia , 2007, Journal of thrombosis and haemostasis : JTH.
[197] M. Milling,et al. Heparin-induced skin necrosis and low molecular weight heparins. , 1999, Annals of the Royal College of Surgeons of England.
[198] A. Greinacher,et al. Heparin-Induced Thrombocytopenia: Frequency and Pathogenesis , 2006, Pathophysiology of Haemostasis and Thrombosis.
[199] A. Trautmann,et al. Heparin allergy: delayed-type non-IgE-mediated allergic hypersensitivity to subcutaneous heparin injection. , 2009, Immunology and allergy clinics of North America.
[200] M. Schindewolf,et al. Incidence and causes of heparin-induced skin lesions , 2009, Canadian Medical Association Journal.
[201] L. Śliwiński,et al. Effects of heparin and low-molecular-weight heparins on bone mechanical properties in rats , 2004, Thrombosis and Haemostasis.
[202] A. Greinacher,et al. [Thrombosis prophylaxis in trauma surgery units in Germany: a survey]. , 2009, Der Unfallchirurg.
[203] J. Kelton,et al. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need? , 2005, The Journal of laboratory and clinical medicine.
[204] J. Amiral,et al. Platelet Factor 4 Complexed to Heparin Is the Target for Antibodies Generated in Heparin-Induced Thrombocytopenia , 1992, Thrombosis and Haemostasis.
[205] Sunil V. Rao,et al. Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: a proposal from the academic bleeding consensus (ABC) multidisciplinary working group. , 2009, American heart journal.
[206] J. Douketis,et al. Dosing practices and risk factors for bleeding in patients receiving enoxaparin for the treatment of an acute coronary syndrome. , 2004, Chest.
[207] N. Weissman,et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. , 2003, The American journal of cardiology.
[208] A. Greinacher,et al. Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin. , 2002, Chest.
[209] S. Yusuf,et al. Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. , 2008, European heart journal.
[210] J. Kelton,et al. Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. , 2005, Blood.
[211] M. Prins,et al. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. , 2010, The Cochrane database of systematic reviews.